Riskpilot← Back to searchSign inGet full accessVISIOPHARM A/S
A/SActiveCVR 26186676Agern Alle 24, 2.Computer consultancy and computer facilities management activities · NACE 6220Est. 200155 employees
Revenue 2025
DKK 130,6M
+11% vs 2024
EBITDA margin
-1.9%
-4% vs 2024
Equity ratio
-5.1%
Financial strength
Net profit 2025
DKK -17,2M
+1% vs 2024
| Revenue | DKK 130,6M | +11% |
| EBITDA | DKK -2,5M | -4% |
| Net profit | DKK -17,2M | +1% |
| Total assets | DKK 97,9M | -17% |
| Equity | DKK -4,9M | -154% |
| Employees | 55 | — |
Legal name
VISIOPHARM A/S
CVR number
26186676
Legal form
Aktieselskab
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
9. juli 2001
Share capital
DKK 1.704.214
Employees
55 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer eller af et bestyrelsesmedlem og en direktør i forening.
Company purpose
Selskabets formål er at drive virksomhed med udvikling og salg af produkter og serviceydelser til brug indenfor drug discovery og anden i forbindelse dermed stående virksomhed.
Address
Agern Alle 24, 2.
Phone
+4588202088
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.335 | 6.364 | 9.283 | 11.752 | 15.846 | 62.451 | 2.575 | 32.393 | 84.262 | 108.495 | 135.974 | 112.093 | 118.186 | 130.617 |
| Staff expenses | -6.567 | -4.915 | -4.981 | -7.745 | -13.415 | -25.996 | -26.572 | -36.470 | -64.732 | -83.742 | -72.620 | -78.395 | -73.425 | -72.974 |
| EBITDA | 768 | 1.449 | 4.302 | 4.007 | 2.432 | 5.954 | -6.458 | -6.608 | -20.186 | -38.464 | -19.068 | -14.496 | -2.391 | -2.486 |
| Depreciation & amort. | 1.853 | -2.242 | -2.403 | -2.785 | -3.071 | -5.496 | 4.511 | 4.361 | -8.920 | -7.759 | -8.737 | -9.585 | -9.989 | -9.314 |
| EBIT | -1.085 | -793 | 1.899 | 1.222 | -640 | 458 | -10.969 | -10.969 | -29.106 | -46.223 | -27.805 | -24.081 | -12.380 | -11.800 |
| Net financials | -163 | -238 | -10 | 10 | -207 | -309 | -5.053 | -14.102 | -2.640 | -512 | 3.478 | -4.447 | -5.084 | -6.183 |
| Profit before tax | -1.248 | -1.031 | 1.890 | 1.233 | -847 | 149 | -16.022 | -25.071 | -31.746 | -46.735 | -24.327 | -28.528 | -17.464 | -17.983 |
| Tax | -290 | -234 | 825 | -23 | -219 | 355 | -2.042 | -2.407 | -5.438 | -5.394 | -3.715 | 1.760 | -101 | -760 |
| Net profit | -958 | -797 | 1.064 | 1.256 | -628 | -206 | -13.980 | -22.664 | -26.308 | -41.341 | -20.612 | -30.288 | -17.363 | -17.223 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9.209 | 10.667 | 12.516 | 19.780 | 20.401 | 49.841 | 117.330 | 98.114 | 154.187 | 133.560 | 107.596 | 128.996 | 118.419 | 97.853 |
| Equity | 5.478 | 5.521 | 6.586 | 13.841 | 13.213 | 22.678 | 97.421 | 74.235 | 100.466 | 59.406 | 33.904 | 25.482 | 9.155 | -4.949 |
| Long-term debt | 0 | 0 | 0 | 238 | 50 | 300 | 6.799 | 5.330 | 7.460 | 4.233 | 19.341 | 41.794 | 36.237 | 32.332 |
| Short-term debt | 3.731 | 5.146 | 5.494 | 4.944 | 6.219 | 25.964 | 1.311 | 18.549 | 46.261 | 69.921 | 54.351 | 61.720 | 73.027 | 70.470 |
| Total debt | 3.731 | 5.146 | 5.494 | 5.183 | 6.270 | 26.264 | 19.909 | 23.879 | 53.721 | 74.154 | 73.692 | 103.514 | 109.264 | 102.802 |
EBITDA margin
-1.9%
This company
15.8%
Market median
-112% vs market
20122025
Equity ratio
-5.1%
This company
38.2%
Market median
-113% vs market
20122025
Return on equity
-1722300000.0%
This company
18.4%
Market median
-9360326187% vs market
20122025
Net profit margin
-13.2%
This company
8.1%
Market median
-263% vs market
20122025
Asset turnover
1.33×
This company
1.12×
Market median
+19% vs market
20122025
Debt / equity
20.77×
This company
0.62×
Market median
-3250% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MG Management | Management | 2001 | — | — |
JD Management | Management | 2006 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2012 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2002 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2001 | — | — | |
| Board of Directors | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Arbejdsmarkedets Tillægspension | Company | 15.0% | 15.0% | 2018 |
IVS FUND II K/S | Company | 10.0% | 10.0% | 2015 |
Johan Doré Holding ApS | Company | 10.0% | 10.0% | 2019 |
Michael Grunkin Holding ApS | Company | 10.0% | 10.0% | 2019 |
Danmarks Eksport- og Investeringsfond | Company | 5.0% | 5.0% | 2023 |
| Individual | 5.0% | 5.0% | 2018 | |
IVS A/S | Company | 5.0% | 5.0% | 2015 |
C.L. DAVIDS FOND OG SAMLING | Company | 5.0% | 5.0% | 2018 |
VISIOPHARM HOLDING ApS | Company | 25.0% | 25.0% | 2018 |
VÆKSTFONDEN | Company | 5.0% | 5.0% | 2018 |
| Individual | 5.0% | 5.0% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BRUHN HOLDING ApS
VISIOPHARM A/S Board members of VISIOPHARM A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Grunkin | Management | 0 companies |
| Johan Doré Hansen | Management | 0 companies |
| Martin Bonde | Board of Directors | 0 companies |
| Susanne Høiberg | Board of Directors | 0 companies |
| Per Arne Rickard Lindelöf | Board of Directors | 0 companies |
| Jens Harpøth Zilstorff | Board of Directors | 0 companies |
| Jeannett Hvidkjær | Board of Directors | 0 companies |
| Claus Henrik Berner Møller | Board of Directors | 0 companies |
| Henrik Stender | Board of Directors | 0 companies |
| Morten Frost Norgreen | Board of Directors | 0 companies |
| Anders Weber | Board of Directors | 0 companies |
| Patrik Olof Dahlén | Chairman | 0 companies |
| Steen Bundgaard Lauritzen | Board of Directors | 0 companies |
| Thomas Weilby Knudsen | Board of Directors | 0 companies |